Thelansis’s “Hepatorenal Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease, characterized by functional kidney failure in the absence of intrinsic renal pathology, most often occurring in patients with cirrhosis and portal hypertension, including those with alcoholic hepatitis or other causes of decompensated liver disease. It is precipitated by circulatory changes that lead to renal vasoconstriction, and common triggers include spontaneous bacterial peritonitis, gastrointestinal bleeding, and large‑volume paracentesis without plasma expansion, while sepsis can also provoke HRS through vasoactive mediator release. Clinically, HRS is classified into two types: Type 1, marked by rapid and severe renal decline with a median survival of less than two weeks, and Type 2, which progresses more slowly and is often associated with refractory ascites, with survival typically ranging from several months depending on liver disease severity. Diagnosis requires exclusion of other causes of kidney injury, and while vasoconstrictor therapy with albumin may provide temporary improvement, liver transplantation remains the only definitive treatment offering long‑term survival.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Hepatorenal Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report
Our team will get in touch with you shortly about the Hepatorenal Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report.